Literature DB >> 29889075

Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis.

Yat-Fung Shea1,2, Warren Barker1, Maria T Greig-Gusto1, David A Loewenstein3, Ranjan Duara1,4, Steven T DeKosky5.   

Abstract

BACKGROUND: Patients with cognitive impairment or dementias of uncertain etiology are frequently referred to a memory disorders specialty clinic. The impact of and role for amyloid PET imaging (Aβ-PET) may be most appropriate in this clinical setting.
OBJECTIVE: The primary objective of this study was to perform a systematic review and meta-analysis of the impact of Aβ-PET on etiological diagnosis and clinical management in the memory clinic setting.
METHODS: A search of the literature on the impact of Aβ-PET in the memory clinic setting between 1 January 2004 and 12 February 2018 was conducted. Meta-analysis using a random effects model was performed to determine the pooled estimate of the impact of Aβ-PET in the changes of diagnoses and changes in management plan.
RESULTS: After rigorous review, results from 13 studies were extracted, involving 1,489 patients. Meta-analysis revealed a pooled effect of change in diagnoses of 35.2% (95% CI 24.6-47.5). Sub-analyses showed that the pooled effect in change in diagnoses if Aβ-PET was used under the appropriate use criteria (AUC) or non-AUC criteria were 47.8% (95% CI 25.9-70.5) and 29.6% (95% CI: 21.5-39.3), respectively. The pooled effect of a change of diagnosis from Alzheimer's disease (AD) to non-AD and from non-AD to AD were 22.7% (95% CI: 17.1-29.5) and 25.6% (95% CI: 17.6-35.8), respectively. The pooled effect leading to a change of management was 59.6% (95% CI 39.4-77.0).
CONCLUSIONS: Aβ-PET has a highly significant impact on both changes in diagnosis and management among patients being seen at a specialty memory clinic.

Entities:  

Keywords:  Alzheimer’s disease; amyloid imaging; diagnosis; management; memory clinic; positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 29889075      PMCID: PMC6323639          DOI: 10.3233/JAD-180239

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  31 in total

1.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

2.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

3.  Impact of molecular imaging on the diagnostic process in a memory clinic.

Authors:  Rik Ossenkoppele; Niels D Prins; Yolande A L Pijnenburg; Afina W Lemstra; Wiesje M van der Flier; Sofie F Adriaanse; Albert D Windhorst; Ron L H Handels; Claire A G Wolfs; Pauline Aalten; Frans R J Verhey; Marcel M Verbeek; Mark A van Buchem; Otto S Hoekstra; Adriaan A Lammertsma; Philip Scheltens; Bart N M van Berckel
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

4.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

5.  Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study.

Authors:  Mathieu Ceccaldi; Thérèse Jonveaux; Antoine Verger; Pierre Krolak-Salmon; Claire Houzard; Olivier Godefroy; Trevor Shields; Audrey Perrotin; Rossella Gismondi; Santiago Bullich; Aleksandar Jovalekic; Nicola Raffa; Florence Pasquier; Franck Semah; Bruno Dubois; Marie-Odile Habert; David Wallon; Mathieu Chastan; Pierre Payoux; Andrew Stephens; Eric Guedj
Journal:  Alzheimers Dement       Date:  2017-11-04       Impact factor: 21.566

6.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Authors:  Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-08       Impact factor: 9.236

7.  [Amyloid positron-emission-tomography with [18 F]-florbetaben in the diagnostic workup of dementia patients].

Authors:  S Schönecker; C Prix; T Raiser; N Ackl; E Wlasich; G Stenglein-Krapf; E Mille; M Brendel; O Sabri; M Patt; H Barthel; P Bartenstein; J Levin; A Rominger; A Danek
Journal:  Nervenarzt       Date:  2017-02       Impact factor: 1.214

8.  Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients.

Authors:  Christopher James Carswell; Zarni Win; Kirsty Muckle; Angus Kennedy; Adam Waldman; Gemma Dawe; Tara D Barwick; Sameer Khan; Paresh A Malhotra; Richard J Perry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-10       Impact factor: 10.154

9.  Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.

Authors:  Y F Shea; J Ha; S C Lee; L W Chu
Journal:  Hong Kong Med J       Date:  2016-06-17       Impact factor: 2.227

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  10 in total

1.  Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints.

Authors:  Yat-Fung Shea; Warren Barker; Maria T Greig-Gusto; David A Loewenstein; Steven T DeKosky; Ranjan Duara
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease.

Authors:  Tanyaluck Thientunyakit; Thonnapong Thongpraparn; Chakmeedaj Sethanandha; Takahiro Yamada; Yuichi Kimura; Weerasak Muangpaisan; Kazunari Ishii
Journal:  Jpn J Radiol       Date:  2021-05-21       Impact factor: 2.374

3.  Tau-PET imaging as a molecular modality for Alzheimer's disease.

Authors:  Cyrus Ayubcha; Grant Rigney; Austin J Borja; Thomas Werner; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-10-15

Review 4.  State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm.

Authors:  Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni
Journal:  Diagnostics (Basel)       Date:  2021-04-27

5.  Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis.

Authors:  Antoine Leuzy; Irina Savitcheva; Konstantinos Chiotis; Johan Lilja; Pia Andersen; Nenad Bogdanovic; Vesna Jelic; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-26       Impact factor: 9.236

Review 6.  Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?

Authors:  Adva Hadar; David Gurwitz
Journal:  Dialogues Clin Neurosci       Date:  2018-12       Impact factor: 5.986

7.  Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.

Authors:  Yi-Wen Bao; Anson C M Chau; Patrick Ka-Chun Chiu; Yat Fung Shea; Joseph S K Kwan; Felix Hon Wai Chan; Henry Ka-Fung Mak
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Authors:  Zahinoor Ismail; Sandra E Black; Richard Camicioli; Howard Chertkow; Nathan Herrmann; Robert Laforce; Manuel Montero-Odasso; Kenneth Rockwood; Pedro Rosa-Neto; Dallas Seitz; Saskia Sivananthan; Eric E Smith; Jean-Paul Soucy; Isabelle Vedel; Serge Gauthier
Journal:  Alzheimers Dement       Date:  2020-07-29       Impact factor: 21.566

9.  Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort.

Authors:  Yi-Wen Bao; Yat-Fung Shea; Patrick Ka-Chun Chiu; Joseph S K Kwan; Felix Hon-Wai Chan; Henry Ka-Fung Mak
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

10.  Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.

Authors:  Insa Feinkohl; Carola G Schipke; Jochen Kruppa; Felix Menne; Georg Winterer; Tobias Pischon; Oliver Peters
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.